Ad Blocker Detected
Our website is made possible by displaying online advertisements to our visitors. Please consider supporting us by disabling your ad blocker.
Merck & Co., Inc. MRK announced that the Ministry of Health, Labor and Welfare (MHLW) in Japan has approved its blockbuster anti-PD-1 therapy, Keytruda (pembrolizumab), for four new cancer indications in the country.
The MHLW has now approved Keytruda in combination with chemotherapy as neoadjuvant treatment and then continued as a monotherapy as adjuvant treatment following surgery in patients with HER2-negative breast cancer, who are at high risk of disease recurrence.
The MHLW also approved Keytruda in combination with chemotherapy, with or without bevacizumab, for the treatment of advanced or recurrent cervical cancer in patients with no prior chemotherapy, who are not amenable to curative treatment.
Keytruda as monotherapy is now approved in Japan for the adjuvant treatment of renal cell carcinoma in certain patients who are at increased risk of recurrence following nephrectomy or following nephrectomy and resection of metastatic lesions.
The MHLW has also approved Keytruda as a monotherapy for the adjuvant treatment of patients with stage IIB or IIC melanoma after complete resection.
Following these latest approvals by the MHLW, Keytruda now has 23 approved uses across 13 different types of cancer indications in Japan.
Shares of Merck have rallied 12% so far this year against the industry’s decline of 6.9%.
Image Source: Zacks Investment Research
Keytruda is already approved for the treatment of several types of cancer indications globally. The drug accounts for around 40% of Merck’s pharmaceutical sales.
Keytruda has played an instrumental role in driving Merck’s revenue growth in the past few years. The drug is continuously growing and expanding into new indications and markets globally.
The Keytruda development program is also progressing well and the drug is being studied for more than 30 types of cancer in more than 1750 studies, including nearly 1300 combination studies. Meanwhile, Keytruda is being studied in phase III studies for biliary tract, gastric, hepatocellular, cutaneous squamous cell, mesothelioma, ovarian, and prostate cancers, among others.
Zacks Rank & Stocks to Consider
Merck currently carries a Zacks Rank #3 (Hold). Better-ranked stocks in the biotech sector include Aptose Biosciences Inc. APTO, Atara Biotherapeutics, Inc. ATRA and ORIC Pharmaceuticals, Inc. ORIC, all carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Aptose Biosciences’ loss per share estimates narrowed by 15.7% for 2022 and 15% for 2023 in the past 60 days.
Earnings of Aptose Biosciences surpassed estimates in three of the trailing four quarters and missed on the remaining occasion. APTO delivered an earnings surprise of 2.23%, on average.
Atara Biotherapeutics’ loss per share estimates narrowed 43.2% for 2022 and 21.3% for 2023 in the past 60 days.
Earnings of Atara Biotherapeutics surpassed estimates in three of the trailing four quarters and missed on the other occasion. ATRA delivered an earnings surprise of 4.83%, on average.
ORIC Pharmaceuticals’ loss per share estimates narrowed 8.6% for 2022 and 22% for 2023 in the past 60 days.
Earnings of ORIC Pharmaceuticals surpassed estimates in three of the trailing four quarters and missed on the remaining occasion. ORIC delivered an earnings surprise of 8.85%, on average.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Merck & Co., Inc. (MRK): Free Stock Analysis Report
Atara Biotherapeutics, Inc. (ATRA): Free Stock Analysis Report
Aptose Biosciences, Inc. (APTO): Free Stock Analysis Report
Oric Pharmaceuticals, Inc. (ORIC): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.